REVIEW
Adverse Health Effects of Indoor Molds
LUKE CURTIS MS, CIH, 1
ALLAN LIEBERMAN MD, 2
MARTHA STARK MD, 3
WILLIAM REA MD 4
AND MARSHA VETTER MD, P H D
51School
of Public Health, University of Illinois at Chicago, Illinois,
2Center
for Occupational and Environmental Health, North Charleston, South
Carolina,
3
Harvard University, Newton Center,
Massachusetts, 4Environmental
Health Center, Dallas, Texas, 5Environmental
Health Center, Hoffman Estates, Illinois, USA
Abstract
Purpose: It has long been known that eating moldy food is hazardous, and
airborne Aspergillus and other fungi can cause life-threatening
illnesses in immuno-compromised patients. However, the possible health
risks of indoor mold exposure in immunocompetent humans are
controversial. This literature review examines the health effects of
indoor airborne exposure to mold.
Design: Literature review.
Materials and Methods: This
review was conducted by searching PubMed and other medical databases, as
well as reading recent conference reports.
Results: Many studies link exposure to damp or moldy indoor conditions
to increased incidence and/or severity of respiratory problems such as
asthma, wheezing and rhinosinusitis. Stachybotrys produces
trichothecenes and other mycotoxins, which can inhibit protein synthesis
and induce hemorrhaging disorders. Indoor mold exposure can alter
immunological factors and produce allergic reactions. Several studies
have indicated that indoor mold exposure can alter brain blood flow,
autonomic nerve function, brain waves and worsen concentration,
attention, balance and memory. Failure to perform the appropriate
objective evaluations on patients may account for the commonly held
belief that indoor mold exposure poses no significant health risks to immunocompetent humans.
Conclusions: Exposure to high levels of indoor mold can cause
injury to and dysfunction of multiple organs and systems, including
respiratory, hematological, immunological, and neurological systems, in
immunocompetent humans.
Keywords: mold, fungi,
mycotoxin, allergy, indoor air quality, asthma, neurotoxicity, lung
hemorrhage, Aspergillus, Penicillium, Cladosporium, Alternaria,
Stachybotrys.
INTRODUCTION
In recent years, public attention has become increasingly focused on
human health concerns linked with mold (fungi) inside homes and
workplaces. Indoor airborne mold exposure has been associated with
adverse human health effects in multiple organs and body systems,
including respiratory, nervous, immune, hematological and dermatological
systems. Indoor mold exposure can also lead to life-threatening systemic
infections in immunocompromised patients. A qualitative systematic
literature review was undertaken in order to examine and JNE (gamma)
JNE51751.3d 23/11/04 18:04:51 Rev 7.51n/W (Jan 20 2003) The Charlesworth
Group, Wakefield +44(0)1924 369598 101014 Journal of Nutritional &
Environmental Medicine (September 2004) 14(3), 114 ISSN 1359-0847
print/ISSN 1364-6907 online/02/010071-02
# 2004 Taylor & Francis Ltd DOI: 10.1080/13590840400010318 appraise the
current state of knowledge about indoor mold-linked health effects, and
to
summarize the available evidence for the use by health professionals.
Physicians, in particular, may encounter patients with common symptoms
occurring in particular
environments, and understanding the potential for mold-related health
effects is key to the complete investigation of those environments.
Physicians and industrial hygienists may be asked to contribute reports
to assist the courts in settling suits. In 2002, an estimated 10,000
mold-related cases were pending in US courts [1]. Also in 2002, the
insurance industry paid out $2 billion in mold-related claims in Texas
alone [2]. Literature was reviewed using the peer-reviewed database, and
from recent conferences on indoor molds. The levels of evidence
available for each topic varied from level I (from at least one properly
randomized controlled trial) through level II (from trials without
randomization, exceptionally convincing uncontrolled experiments, cohort
or casecontrol studies), to level III (opinion of respected authorities
based on clinical experience, descriptive studies, or reports of expert
committees) [3]. [Return to MH]
MOLDS IN THE INDOOR ENVIRONMENT
Fungi (or molds) are ubiquitous in both indoor and outdoor environments
and are frequently dispersed by airborne spores. Mold and mold spores
require moisture and a
food source, such as cellulose or decaying food, to grow [4]. As mold
spores swell with water and grow, they elongate, forming balloon-like
protuberances (hyphae), which secrete digestive enzymes and mycotoxins.
The fungi then digest the food source to support their growth. About
100,000 fungal species have already been identified; in fact, fungi are
estimated to comprise an astounding 25% of the world's biomass [5].
Various surveys of homes in North America and Europe have reported that
visible mold and/or water damage are common, found in 2398% of all
homes examined [69]. There are no official standards at this time for
indoor airborne fungi concentrations. However, indoor fungal levels
above a range of 1501000 colony-forming units per cubic meter of air (cfu
m 2 3 ) are considered to be
sufficient to cause human health problems [7, 1012]. Numerous reports
have documented that indoor air can be contaminated with fungal spore
levels well in excess of 1000 cfu m 2 3 [1320]. The most common indoor
fungal genera collected are Cladosporium, Aspergillus and Penicillium
[1320]. Alternaria, Stachybotrys, Rhizopus, Mucor, Wallemia,
Trichoderma, Chaetomium, yeasts, Botrytis, Epicoccum and Fusarium
species are often found indoors as well [1320].
[Return to MH]
MOLD-RELATED HEALTH SYMPTOMS
Patients have been reporting multiple ill health effects linked to
exposures to mold. Studies of more than 1600 patients suffering ill
effects associated with fungal exposure were presented at one meeting in
Dallas in 2003 (21st Annual Symposium of Man and His Environment,
Dallas, Texas, 1922 June 2003) [2125].
To cite a few studies: Lieberman [21] examined 48 heavily mold-exposed
patients who had the following health problems: muscle and/or joint pain
(71%), fatigue/weakness (70%), neurocognitive dysfunction (67%),
sinusitis (65%), headache (65%), gastrointestinal problems (58%),
shortness of breath (54%), anxiety/depression/irritability (54%), vision
problems (42%), chest tightness (42%), insomnia (40%), dizziness (38%),
numbness/tingling (35%), laryngitis (35%), nausea (33%), skin rashes
(27%), tremors (25%) and heart palpitations (21%). Rea et al.'s study
[23] of 150 heavily indoor mold-exposed patients
found the following health problems: fatigue (100%), rhinitis (65%),
memory loss and other neuropsychiatric problems (46%), respiratory
problems (40%), fibromyalgia (29%), irritable
2
bowel syndrome (25%), vasculitis (4.7%) and angioedema (4.0%). These
clinical reports suggest that there can be multisystem adverse effects
of airborne mold. All reported cases had environmental mold exposure
consistent with toxic mold exposure.
[Return to MH]
MECHANISMS OF MOLD-RELATED HEALTH EFFECTS
Fungi can exert ill health effects
by three major mechanisms: allergy, toxicity, and infection.
Allergy and Irritation
At least 70 allergens have been well
characterized from spores, vegetative parts and small particles from
fungi (0.3 mm and smaller) [26, 27]. A review of 17 studies revealed
that 610% of the general population and 1550% of atopics had immediate
skin sensitivity to fungi [28]. Fungi produce beta glucans, which have
irritant properties [29].
Toxicity
Fungi produce a wide variety of toxic
chemicals called mycotoxins [4, 30, 31]. Some common mycotoxins include:
aflatoxinsvery potent carcinogens and hepatotoxins, produced by some
Aspergillus species; ochratoxinsnephrotoxic and carcinogenic, produced
by some Aspergillus and Penicillium; sterigmatocystinimmunosuppressive
and a liver carcinogen, produced by Aspergillus species, especially A.
versicolor; trichothecenesproduced primarily by Stachybotrys and
Fusarium species and have been reported to inhibit protein synthesis and
cause hemorrhage and vomiting. Fungi also produce beta glucans, which
have immunological effects [32]. The smell of molds comes primarily from
volatile organic compounds [33]. Adverse human and animal effects from
mycotoxin-contaminated foodstuffs have been well recognized since the
early twentieth century [30, 34], but the pathway of mycotoxin injury
through inhalation is questioned [35]. Because it is unethical to
conduct controlled studies on humans with inhaled mycotoxin exposure,
only controlled animal exposures and human cohort and casecontrol
studies can be carried out. The literature reveals that significant
amounts of mycotoxins (including ochratoxin, sterigmatocystin and
trichothecenes) are present in indoor dust [3639] and dust or fungal
particles less than 10 mm in diameter are respirable, thus allowing
absorption of mycotoxins through the lungs [31, 34, 40, 41].
[Return to MH]
Patients exposed to indoor Stachybotrys
have been found to have measurable blood levels of the Stachybotrys
hemorrhagic toxin stachylysin [42]. Levels of trichothecene mycotoxins
in urine have also been found in significantly higher levels in patients
exposed to high indoor fungal levels as opposed to an unexposed control
group [43]. Blood ochratoxin levels have been found to be significantly
higher in food industry workers exposed to airborne ochratoxin vs.
unexposed controls [39]. These findings support an inhalation pathway
for entry of mycotoxins into the body.
[Return to MH]
Infection
Fungi such as Candida, Histoplasmosis,
Cryptococcus, Blastomyces and Coccidioides can infect immunocompetent
people [44]. Fungi such as Trichophyton, Candida and Malasezia commonly
cause minor skin infections in immunocompetent humans [45].
Serious infections by such fungi as Candida, Aspergillus and
Pneumocystis mostly involve severely immunocompromised patients [4547].
In recent years, the incidence of life-threatening infections in
immunocompromised patients from Aspergillus and other common serious infections by such fungi as Candida, Aspergillus and Pneumocystis mostly involve severely immunocompromised patients [4547].
In recent years, the incidence of life-threatening infections in
immunocompromised patients from Aspergillus and other common3 fungi has
been growing rapidly [48, 49]. Invasive aspergillosis is very common
among immunocompromised patients, with the following reported incidence
rates: lung transplants: 1726%; allogenic bone marrow transplants:
515%; acute leukemia: 524%; heart transplants: 213% [5051]. Even
with strong anti-fungal drugs and intense hospital
treatment, mortality rates from invasive aspergillosis range from 50 to
99% in the immunocompromised [52, 53].
[Return to MH]
SAMPLING FOR MOLD EXPOSURE
Indoor fungal sampling is most commonly performed by measuring airborne
levels of viable (culturable) or total (viable and non-viable) spores
[54, 55]. Some of the airborne viable sampling methods, such as Andersen
samplers, collect air for only a few minutes. Settle plates are an
inexpensive method to obtain a semi-quantitative measure of indoor
airborne fungi levels. Viable and non-viable airborne spore counts can
vary considerably over a period of minutes, so air sampling over several
periods of time may be necessary to accurately characterize airborne
fungal spore levels [54, 55]. However, airborne fungi measurements fail
to take into consideration mold contamination in dust or surfaces (often
visible to the naked eye) and mycotoxins in air, dust and on surfaces
[54, 56]. Therefore,
testing settled dust for fungi and mycotoxins has been recommended [54,
55]. Other techniques, such as polymerase chain reaction (PCR),
enzyme-linked immunosorbent assay (ELISA), and measurement of fungal
volatile organic compounds, polysaccharides, ergosterol and beta glucans,
have also been found to be useful in assaying indoor environments for
molds, their allergens and mycotoxins [54].
[Return to MH]
INDOOR MOLD EXPOSURE AND HEALTH EFFECTS IN BODY SYSTEMS
Respiratory System
Many epidemiological studies have noted that residential exposure to
molds and/or chronic dampness can increase asthma/wheezing incidence or
morbidity in both children and adults [79, 5770]. Asthma and related
conditions are very common in the USA, with an overall prevalence of
about 5.4% among all age groups and incidences as high as 27% in inner
city children [71]. Studies with infants have reported that higher
fungal exposures are associated with more wheezing, coughing and
respiratory illness [72, 73]. Higher indoor beta glucan levels have been
associated with significantly higher levels of chest tightness and joint
pain
[74]. Non-industrial occupational mold exposure has been reported to be
associated with significantly higher levels of asthma, sinusitis,
irritated skin and eyes, and chronic fatigue [7579]. One study found
that patients exposed to high indoor fungal levels had significantly
lower lung function than unexposed controls [24]. Higher outdoor fungal
concentrations have been linked to higher asthma death rates [80] and
higher asthma incidence [8183] in children or young adults. Challenge
exposures with Penicillium and Alternaria extracts equivalent to high
outdoor levels of fungi were noted to severely lower lung function in
asthmatics [84]. Skin sensitivity to Alternaria has been linked to much
higher risk (odds ratio 190, 95% confidence interval 6.56.536,
pv0.0001) of respiratory arrest [85]. Various epidemiological studies
have associated skin sensitivity to common indoor fungi and higher
asthma incidence or severity [8690] and higher rates of sinusitis
[91]. Airborne fungal exposure is known to cause bronchopulmonary
aspergillosis and hypersensitivity pneumonitis, and can cause sinusitis
[92, 93]. An estimated 14% of the US population suffers from
rhinosinusitis and related conditions [94]. Allergic fungal sinusitis
was diagnosed on the basis of fungal growth in nasal secretions and the
presence of allergic mucin in 93% of 101 consecutive patients undergoing
sinus surgery [94]. Another study was able to recover and culture fungi
from the sinuses of 56% of 45 patients undergoing endoscopic sinus
surgery for chronic rhinosinusitis [95]. A long-term cohort study
of 639 patients with allergic fungal sinusitis demonstrated that
remedial steps taken to reduce fungal exposure (by utilizing, for
example, air filters, ionizers, moisture control and anti-microbial
nasal sprays) significantly reduced rhinosinusitis and improved nasal
mucosa morphology [22]. This study concluded that failure to reduce
airborne fungi levels to less than four per hour on a settle plate
failed to resolve the sinusitis [22]. Although, historically,
anti-fungal drugs have generally not been recommended for the treatment
of fungal sinusitis [92, 93], recent observational studies have found
beneficial effects of oral and nasal medication for sinusitis patients
[22, 96]. Several studies have linked residential exposure to various
fungi with hypersensitivity pneumonitis [9799].[Return
to MH]
Hematological Effects
Exposure to high indoor levels of Stachybotrys, Aspergillus and other
fungi has been epidemiologically associated with infant lung hemorrhage
[100104]. Although questions were raised after this association was
discovered [105], it meets many epidemiological criteria for causality
[106]. Acute infant pulmonary hemorrhage can be rapidly fatal; when the
infant survives, lung blood vessel damage is present and deposits of
hemosiderin will remain in the lung macrophages and can be seen in
tissue obtained during bronchoscopy [101]. Stachybotrys fungi produce a
wide range of trichothecene mycotoxins (including satratoxins and T2),
several roridin epimers, verrucarin J and B and hemolysin [31, 103]. A
hemorrhagic protein called stachylysin has been isolated from
Stachybotrys collected from
homes of infants with lung hemorrhage [107, 108] and from serum of
patients with residential Stachybotrys exposure [42]. It is hypothesized
that infants with their rapidly growing lungs are more susceptible to
the toxic effects of Stachybotrys mycotoxins [109]. Studies with
Stachybotrys-exposed adults have noted a significantly higher incidence
of health conditions such as wheezing, skin and eye irritation,
'flu-like symptoms and chronic fatigue [110]. Stachybotrys has been
isolated from the lungs of a child with pulmonary hemosiderosis [111]. A
case study was presented of 16-month-old twins in a mold-infested home,
one of whom died of pulmonary hemosiderosis [112]. High levels of
trichothecene mycotoxins were found in the lungs and liver of the dead
infant, while high IgG levels to Stachybotrys and IgM
levels to satratoxin and trichothecenes were found in the serum of the
surviving infant. Environmental sampling in the twins' home found high
levels of satratoxin as well as high levels of spores from Stachybotrys,
Aspergillus versicolor and Penicillium [112].
[Return to MH]
Immune System
Some studies have reported that indoor fungi-exposed patients have
higher serum levels of IgG, IgA and IgM antibodies to common fungi,
trichothecenes and satratoxins [113115]. IgG antibodies to nine common
indoor fungi were significantly higher in subjects with sinusitis vs.
non-sinusitis subjects in a moldy school [116]. Other studies have noted
no significant increases in fungal IgG [117, 118] or fungal IgE [113] in
fungi-exposed patients. Indoor fungal exposure has been associated with
altered levels of T4, T8 and natural killer cells and higher levels of
autoantibodies [23, 25, 119, 120]. Occupants of homes with high Indoor
glucan exposure had a lower proportion of cytotoxic t-cells (CD8zSF61z)
and higher secretion of tumor necrosis factor than occupants of homes
with lower levels of beta glucans [121]. Studies of animals given such
common mycotoxins as aflatoxins, ochratoxins and trichothecenes orally
showed considerable immune impairment, including depression
of T cells, B cells and macrophages [122]. Human cell line studies have
also found that many mycotoxins can suppress T-cell, B-cell and natural
killer cell activity at serum concentrations similar to those found in
indoor mold-exposed patients [123]. Central Nervous System Two case
series of 48 and 150 mold-exposed patients found significant fatigue and
weakness in 70100% of cases, and neurocognitive dysfunction including
memory loss, irritability, anxiety and depression in over 40% of the
patients [21, 23]. Numbness, tingling and tremor were also found in a
significant number of patients [21, 23]. These signs and symptoms have
been described as classic manifestations of neurotoxicity [124]. A study
of 43 mold-exposed patients found that they performed significantly
worse than 202 controls on many neuropsychiatric tests, including
balance sway speed, blinking reflex, color perception, reaction times
and left grip strength (pv0.0001) [125]. Quantitative
electroencephalogram (qEEG) studies in 182 patients with documented mold
exposure also noted significant alterations in brain waves, including
hypoactivation of the frontal cortex and narrowed frequency bands [126].
Higher levels of mold exposure (longer time in mold-infested area,
presence of Stachybotrys or higher cfu m
air) were associated with significantly more abnormal qEEGs as well as
significantly worse scores of concentration and motor and verbal skills
in these 182 patients [126]. A triple-headed SPECT brain scan revealed
neurotoxic patterns in 26 of 30 (87%) mold-exposed patients [127]. An
iriscorder study of autonomic nervous function in 60 mold-exposed
patients found that 95% had abnormal autonomic responses of the pupil
compared with the population reference range
[23]. Visual contrast sensitivity studies were often abnormal in indoor
mold-exposed patients [23]. Additional studies have reported that
mold-exposed patients do significantly worse on tests of attention,
balance, reaction time, verbal recall, concentration, memory, and finger
tapping compared with the general population reference range [24, 128,
129]. [Return to MH]
Most of these patients also experienced
many health problems, including chronic fatigue, headaches, insomnia and
decreased balance, concentration and attention. Studies of indoor
mold-exposed children and adults found significantly more
neurophysiological abnormalities vs. controls, including abnormal EEGs
and abnormal brainstem, visual and somatosensory evoked potentials [25,
130, 131]. Lieberman [21] presented a case series of 12 patients who
developed tremors following
documented heavy indoor mold exposure. Numerous articles have reported
domestic dogs developing tremors following ingestion of moldy food
[132134]. Territrem b, a mycotoxin produced by the common fungus
Aspergillus terreus, has been shown to be an irreversible binder and
inhibitor of acetylcholinesterase [135].
Renal System
It is known that ochratoxin-contaminated food is nephrotoxic [136, 137].
Indoor airborne exposure to ochratoxin may also be nephrotoxic. In a
case report of a family presenting with increasing thirst/urination,
lethargy, and skin rash, a considerable amount of ochratoxin was found
in their house dust. The family recovered after moving to another home
[36]. [Return to MH]
Reproductive System
The literature suggests a relationship between heavy airborne fungal
exposure and reproductive dysfunction. Kristensen et al. [138, 139]
reported that airborne mycotoxin exposures in Norwegian grain farmers
was significantly related to higher rates of pre-term deliveries,
late-term miscarriages and higher rates of endometrial and ovarian
endocarcinoma. The veterinary literature finds a strong association
between mycotoxtins in feedstuffs and reproductive problems [140].
Diabetes
There is a great deal of evidence that links environmental factors to
the triggering of type 1 diabetes. Exposure to viruses, bacteria and
mycotoxins such as alloxan, streptozatocin and L-asparginase has been
linked to the development of type 1 diabetes in animals and humans
[141143]. Lieberman [21] reported that in a single year, five of his
patients developed type 1 diabetes following documented heavy indoor
mold exposure.
DIAGNOSIS AND MANAGEMENT OF
POTENTIALLY MOLD-RELATED HEALTH PROBLEMS
A careful medical and environmental
history is an essential first step in evaluating a patient for
mold-related health problems [144147]. Particular attention should be
paid to any history of exposure to visible mold and/or water damage at
the home or workplace. Environmental sampling for viable spores, total
spores, and mycotoxins in the air and dust can provide important
exposure information. For a helpful overview of sampling methods, see
references [54, 148, 149]. For an informative guide to the
classification, identification and biology of common indoor fungi, see
reference [4]. Several good guides exist for the prevention and
remediation of indoor fungi problems [144, 148151]. For patients
suspected of having substantial fungal exposure, a battery of
sophisticated laboratory tests has been developed: a basic metabolic
panel to test for several important parameters (including electrolytes,
blood sugar, liver and kidney status); measurement of antibodies to
molds and mycotoxins in serum [113, 114]; immune tests for
autoantibodies, complement, gamma globulins and lymphocyte panels [120];
urine and blood testing for
mycotoxins [43]; visual contrast sensitivity tests; and pupillometry and
heart rate variation to assist in the evaluation of autonomic nervous
system function. The use of standard neuropsychological test batteries
[23, 128130], EEG and brain imaging techniques such as SPECT and
magnetic resonance imaging (MRI) can be very helpful tools in
documenting neurological damage [25,125, 127, 131, 145].
Pulmonary function tests are also
useful for patients with respiratory symptoms [24, 124]. Failure to
perform objective evaluations to access system or organ dysfunction
account for the presently accepted position that airborne mold exposures
have no significant adverse effects [35]. If end-stage organ damage
is suspected, consultation with a specialist may be useful. Other common
indoor environmental exposures should also be considered as a potential
source of health problems. Common non-fungal indoor environmental
factors include poor ventilation, carbon monoxide from faulty heat
sources, leaking natural gas, pesticides, wood smoke, second-hand
tobacco smoke, petrochemicals, such as cleaners/building
materials/solvents, formaldehyde from outgassing carpets, building
materials, bacteria, and allergens from the fur, feathers, saliva and
excrement of common household animals such as cockroaches, dust mites,
cats, dogs, mice, rats, caged birds, and pigeons. Exposure to ozone,
second-hand tobacco smoke, cockroach allergens, formaldehyde, and viral
infections have been noted to have a synergistic effect with fungal
exposure to worsen asthma and rhinitis [152156]. The most important
part of treatment for mold-exposed patients, symptomatic or not, is
avoidance of fungal exposure and remediation of mold contamination in
the home and workplace. Any water leaks and damage from flooded or damp
areas should be rectified immediately. Non-porous surfaces such as
floors and walls that have visible mold growth should be cleaned. Porous
waterlogged materials like carpet and furniture should be discarded.
Control of humidity is important to control mold growth. The use of air
conditioners and dehumidifiers can significantly reduce summertime
indoor airborne mold concentrations [13, 157]. HEPA air filters can also
significantly reduce indoor airborne fungi concentrations [158]. For
cleaning severe indoor water or mold problems, the use of protective
equipment like face masks and/or the use of a professional remediation
firm may be essential [148151].
[Return to MH]
Environmental control plays a key role
in preventing Aspergillus infections. Several studies have linked
hospital construction work to increased rates of invasive aspergillosis
[159162]. Environmental controls such as using HEPA filters, sealing
rooms, regular cleaning of rooms, and using anti-fungal
copper-8-quionolate paint have been shown to both significantly reduce
airborne levels of Aspergillus and significantly reduce rates of
invasive aspergillosis in immunocompromised hospital patients [158,
160165]. Other recent research has indicated that a large number of
Aspergillus spores can spread through water supplies [166] and that
cleaning shower facilities can significantly lower airborne levels of
Aspergillus [167]. [Return to MH]
Use of sublingual or fungal
immunotherapy by injection has been shown to be beneficial to some
patients sensitized to common indoor molds such as Alternaria and
Cladosporium herbarium [168, 169]. Some studies with laboratory
animals suggest that a high-quality diet with adequate antioxidant
vitamins, selenium, phytochemicals, methionine and total protein can
reduce the harmful effects of food mycotoxins [170, 171].
SUMMARY
There is an accumulated weight of evidence linking indoor airborne mold
and/or mycotoxin exposures to multisystem adverse human health effects.
A history of new
neurocognitive symptoms occurring in patients soon after heavy mold
exposure, accompanied by objective neuropsychological findings in such
patients, adds considerably to the weight of evidence from animal
studies, epidemiological research, and case series. Health care
professionals, building managers, homeowners and the general public need
to be much more aware of the potential adverse health effects of high
indoor fungal exposures and the need for proper building construction,
maintenance, and remediation of dampness to prevent such effects.
Potentially mold-related illnesses need to be considered in differential
diagnoses, and careful exposure histories taken. Prompt removal from
exposure to fungal contamination remains the treatment of choice, with
some evidence that immunotherapy and nutritional support are also
useful. Indoor airborne mold particles can be irritative to the
respiratory tract, and fungal spores, antigens, volatile organic
compounds, and mycotoxins can be absorbed through the respiratory route
to provoke injury by the mechanisms of allergy, toxicity, and infection.
REFERENCES
[1]
Umberger M. The start that upstaged the economy. Chicago Tribune, 13
January 2002, available
at WL 2612028, database ALLNEWS.
[2]
Mold claims hit $4 billion in Texas, Insurance Journal, 27 May 2003
(http://insurancejournal.
com).
[3]
The Canadian Task Force on the Periodic Health Examination. The Canadian
Guide to Clinical
Preventative Health Care. Ottawa: Supply and Services Canada, 1994.
[4]
Samson R, Hoekstra E, Frisvad J, Filtenborg O. Introduction to Food and
Airborne Fungi.
Utrecht: Centraalbureau voor Schimmelcultures, 2000.
[5]
Miller JD. Fungi as contaminants of indoor air. Atmos Environ 1992;
26A(12): 216272.
[6]
Presternon DR. Perceived moisture problems in Iowa homes. Technical
note. Forest Products J
1991; 41(6): 4748.
[7]
Platt S, Martin C, Hunt S, Lewis C. Damp housing, mould growth and
symptomatic health state.
Br Med J 1989; 298: 16738.
[8]
Brunekreef B, Dockery D, Speizer FE. Home dampness and respiratory
morbidity in children.
Am Rev Resp Dis 1989; 140: 13637.
[9]
Dales R, Zwanenburg H, Burnett R, Franklin C. Respiratory health effects
of home dampness
and molds among Canadian children. Am J Epidemiol 1991; 134(2): 196203.
[10]
Etzel R. Indoor air pollutants in homes and schools. Pediatr Clin North
Am 2001; 48(5): 115365.
[11]
Flannigan B, McCabe E, McGarry F. Allergic and toxigenic microorganisms
in houses. J Appl
Bacteriol 1991; 70: 61S73S.
[12]
Dhillion M. Current status of mold immunotherapy. Ann Allergy 1991; 66:
385.
[13]
Curtis L, Ross M, Persky V et al. Bioaerosol concentrations in the Quad
Cities 1 year after the
1993 Mississippi River floods. Indoor Built Environ 2000; 9: 3543.
[14]
Shelton B, Kirkland K, Flanders WD, Morris G. Profiles of airborne fungi
in buildings and
outdoor environments in the United States. Appl Environ Microbiol 2002;
68(4): 174353.
[15]
Ren P, Jankun T, Leaderer B. Comparisons of seasonal fungal prevalence
in indoor and outdoor
air and in house dwellings in one Northeast American county. J Exposure
Anal Environ
Epidemiol 1999; 9: 5608.
[16]
Pei-Chih W, Huey-Jen S, Chia-Yin L. Characteristics of indoor and
outdoor airborne fungi at
suburban and urban homes in two seasons. Sci Total Environ 2000; 253:
1118.
[17]
Li CS, Kuo YM. Characteristics of airborne microfungi in subtropical
homes. Sci Total Environ
1994; 155(3): 26771.
[18]
Ebner E, Hasselwandter K, Frank A. Indoor and outdoor incidence of
airborne fungal allergens
at low and high alpine environments. Mycol Res 1992; 97: 11724.
[19]
Solomon WR. A volumetric study of winter fungus prevalence in the air of
midwestern homes.
J Allergy Clin Immunol 1976; 57(1): 4655.
[20]
Beaumont F, Kauffman HF, Sluiter HJ, DeVries K. A
volumetric-aerobiological study of
seasonal fungus prevalence inside and outside dwellings of asthmatic
patients living in northeast
Netherlands. Ann Allergy 1984; 53(6): 48692.
[21]
Lieberman A. Explosion of mold cases in homes, workplaces and
occupational medicine
practices. Presented at the 21st Annual Symposium on Man and His
Environment in Health and
Disease, Dallas, Texas, 1922 June 2003.
[22]
Dennis D. Chronic sinusitis: defective T-cells responding to
superantigens, treated by reduction of
fungi in the nose and air. Arch Environ Health 2003; 58(7): 43341.
[23]
Rea WJ, Didriksen N, Simon TR, Pan Y, Fenyves EJ, Griffiths B. Effects
of toxic exposure to
molds and mycotoxins in building-related illnesses. Arch Environ Health
2003; 58(7): 399405.
[24]
Kilburn KH. Indoor mold exposure associated with neurobehavioral and
pulmonary impairment:
a preliminary report. Arch Environ Health 2003; 58(7): 3908.
[25]
Campbell A, Thrasher J, Madison R, Vojdani A, Gray M, Johnson A. Neural
autoantibodies and
neurophysiologic abnormalities in patients exposed to molds in water
damaged buildings. Arch
Environ Health 2003; 58(8): 46478.
[26]
Kurup V, Shen HD, Vijay H. Immunobiology of fungal allergens. Int Arch
Allergy Immunol
2002; 129: 1818.
[27]
Gorny RL, Reponen T, Willeke K et al. Fungal fragments as indoor air
contaminants. Appl
Environ Microbiol 2002; 68: 352231.
[28]
Institute of Medicine. Clearing the Air. Asthma and Indoor Exposures.
Institute of Medicine
[29]
Korpi A, Kasanen JP, Kosma VM, Rylander R, Pasanen AL. Slight
respiratory irritation but not
inflammation in mice exposed to (1w3)-beta-D-glycan aerosols. Mediat
Inflamm 2003; 12(3):
13946.
[30]
Etzel R. Mycotoxins. J Am Med Assoc 2002; 287(4): 4257.
[31]
Nielsen KF. Mycotoxin production by indoor molds. Fungal Genet Biol
2003; 39: 10317.
[32]
Rylander R. Indoor air-related effects and airborne (1w3)-beta-D-glucan.
Environ Health
Perspect 1999; 107(Supplement 3): 5013.
[33]
Wilkins K, Larsen K, Simkus M. Volatile metabolites from mold growth on
building materials
and synthetic media. Chemosphere 2000; 41(3): 43746.
[34]
Bennett J, Klich M. Mycotoxins. Clin Microbiol Rev 2003; 16(3): 497516.
[35]
Hardin B, Kelman B, Saxon A. ACOEM evidence base statement. Adverse
health effects
associated with molds in the indoor environment. J Occup Environ Med
2003; 45(5): 4708.
[36]
Richard J, Plattner R, May J, Liska S. The occurrence of ochratoxin A in
dust collected from a
problem household. Mycopathologica 1999; 146(2): 99103.
[37]
Smoragiewicz W, Cossette B, Boutard A, Krystyniak K. Trichothecene
mycotoxins in the dust of
ventilation systems in office buildings. Int Arch Occup Environ Health
1993; 65(2): 1137.
[38]
Engelhart S, Loock A, Skutlarek D et al. Occurrence of toxigenic
Aspergillus versicolor isolates
and sterigmatocystin in carpet dust from damp indoor environments. Appl
Environ Microbiol
2002; 68(8): 388690.
[39]
Iavacoli I, Brera C, Carelli G, Caputi R, Marinaccio A, Miraglia M.
External and internal dose in
subjects occupationally exposed to ochratoxin A. Int Arch Occup Environ
Health 2002; 75(6): 3816.
[40]
Fischer G, Dott W. Relevance of airborne fungi and their secondary
metabolites for
environmental, occupational and indoor hygiene. Arch Microbiol 2003;
179: 7582.
[41]
Sorenson WG. Fungal spores: hazardous to health? Environ Health Perspect
1999; 107
(Supplement 3): 46972.
[42]
Van Emon J, Reed A, Yike I, Vesper S. ELISA measurement of stachylysin
in serum to quantify
human exposures to the indoor mold Stachybotrys charatarum. J Occup
Environ Med 2003; 45:
58291.
[43]
Croft W, Jastromski BM, Croft AL, Peters HA. Clinical confirmation of
trichothecene
mycotoxicosis in patient urine. J Environ Biol 2002; 23(3): 30120.
[44]
Johnson P, Sarosi G. Community acquired fungal pneumonias. Semin Resp
Infect 1989; 4(1):
5663.
[45]
Tierney L, McPhee S, Papadakis M. Current Medical Diagnosis and
Treatment. New York:
Lange Medical Books, 2003.
[46]
Nicod L, Pache J, Howarth N. Fungal infections in transplant recipients.
Eur Resp J 2001; 17(1):
13340.
[47]
Garber G. An overview of fungal infections. Drugs 2001; 61(Supplement
1): 112.
[48]
Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K.
Trends in
the postmortem epidemiology of invasive fungi at a university hospital.
J Infect 1996; 33:
2332.
[49]
Husain S, Alexander BD, Munoz P et al. Opportunistic mycelial fungal
infections in organ
transplant recipients: emerging importance of non-Aspergillus fungi.
Clin Infect Dis 2003; 37(2):
2219.
[50]
Denning D. Report on a European Science Foundation Workshop on Invasive
Aspergillosis,
2122 October 1998, University of Manchester, Manchester.
[51]
Kontoyiannis D, Bodey G. Invasive aspergillosis in 2002: an update. Eur
J Clin Microbiol Infect
Dis 2002; 21: 16172.
[52]
Denning D. Therapeutic outcome in invasive aspergillosis. Clin Infect
Dis 1996; 23(3): 60815.
[53]
Lin S, Schranz J, Teutsch S. Aspergillosis case-fatality rate: systemic
review of the literature. Clin
Infect Dis 2001; 32(3): 35866.
[54]
Pasanen AL. A review: fungal exposure assessment in indoor environments.
Indoor Air 2001; 11:
8798.
[55]
Dillon HK, Miller JD, Sorenson WG, Douwes J, Jacobs R. Review of methods
applicable to the
assessment of mold exposure in children. Environ Health Perspect 1999;
107(Supplement 3):
47380.
[56]
Tiffany J, Bader H. Detection of Stachybotrys charatarum: the
effectiveness of culturable-air
sampling and other methods. Environ Health 1999; 2000: 911
[57]
Gent J, Ren P, Belanger K et al. Levels of household mold associated
with respiratory symptoms
in the first year of life in a cohort at risk for asthma. Environ Health
Perspect 2002; 110(12):
A7816.
[58]
Dales R, Burnett R, Zwanenburg H. Adverse health effects among adults'
exposures to home
dampness and molds. Am Rev Resp Dis 1991; 143: 5059.
[59]
Ostro B, Lipsett M, Mann J, Braxton-Owens H, White M. Air pollution and
exacerbation of
asthma in African-American children in Los Angeles. Epidemiology 2001;
12: 2008.
[60]
Zock J, Jarvis D, Lucynska G, Sunyer J, Burney P. Housing
characteristics, reported mold
exposure, and asthma in the European Community Respiratory Health
Survey. J Allergy Clin
Immunol 2002; 110(2): 28592.
[61]
Williamson I, Martin C, McGill G. Damp housing and asthma: a case
control study. Thorax
1997; 52: 22934.
[62]
Verhoeff AP, Van Strien RT, Van Wijnen JH, Brunekreef B. Damp housing
and household
respiratory symptoms: the role of sensitization to dust mites and molds.
Am J Epidemiol 1995;
141: 10310.
[63]
Strachan DP, Flannigan B, McCabe E, McGarry F. Quantification of
airborne moulds in the
homes of children with and without wheeze. Thorax 1990; 45: 3827.
[64]
Brunekreef B. Damp housing and adult respiratory symptoms. Allergy 1992;
47: 498502.
[65]
Waegemaekers M, Van Wageningen N, Brunekreef B, Boleij JS. Respiratory
symptoms in damp
homes. A pilot study. Allergy 1989; 44: 1928.
[66]
Jedrychowski W, Flak E. Separate and combined effects of the indoor and
outdoor air quality on
chronic respiratory symptoms adjusted for allergy among preadolescent
children. Int J Occup
Med Environ Health 1998; 11: 1935.
[67]
Hu FB, Persky V, Flay BR, Richardson J. An epidemiological study of
asthma prevalence and
related factors among young adults. J Asthma 1997; 34(1): 6776.
[68]
Jaakkola J, Jaakkola N, Ruotsalainen R. Home dampness and molds as
determinants of
respiratory symptoms and asthma in pre-school children. J Exposure Anal
Environ Epidemiol
1993; 3(Supplement 1): 12642.
[69]
Slezak J, Persky V, Kviz F, Ramakrishnan V, Byers C. Asthma prevalence
and risk factors in
selected Head Start sites in Chicago. J Asthma 1998; 35(2): 20312.
[70]
Lee YL, Lin YC, Hsiue TR, Hwang BF, Guo YL. Indoor and outdoor
environmental exposures,
parental atopy and physician diagnosed asthma in Taiwanese
schoolchildren. Pediatrics 2003;
112(5): e38995.
[71]
Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy
Asthma Immunol
1999; 82(3): 23348.
[72]
Belanger K, Beckett W, Triche E et al. Symptoms of wheeze and persistent
cough in the first year
of life: associations with indoor allergens, air contaminants, and
maternal history of asthma. Am
J Epidemiol 2003; 158: 195202.
[73]
Stark PC, Burge HA, Ryan LM, Milton DK, Gold DR. Fungal levels in the
home and lower
respiratory tract illness in the first year of life. Am J Resp Crit Care
Med 2003; 168(2): 2327.
[74]
Thorn J, Rylander R. Airways inflammation and glucan in a rowhouse area.
Am J Resp Crit Care
Med 1998; 157: 1798803.
[75]
Chao HJ, Schwartz J, Milton DK, Burge HA. The work environment and
workers' health in 4
large office buildings. Environ Health Perspect 2003; 111(9): 12428.
[76]
Pirhonen I, Nevalainen A, Husman T. Home dampness, moulds and their
influence on respiratory
infections in Finland. Eur Resp J 1996; 9: 261822.
[77]
Koskinen OM, Husman TM, Meklin TM. The relationship between mould and
moisture
observations in houses and state of health of their occupants. Eur Resp
J 1999; 14: 13637.
[78]
Ruotsalainen R, Jaakola N, Jaakola J. Dampness and molds in day-care
centers as an
occupational health care problem. Int Arch Occup Environ Health 1995;
66: 36974.
[79]
Wan GH, Li CS. Dampness and airway inflammation and systemic conditions
in office building
workers. Arch Environ Health 1999; 54: 5863.
[80]
Targonski P, Persky V, Ramakrishnan V. Effect of environmental molds on
risk of death from
asthma during the pollen season. J Allergy Clin Immunol 1995; 95(5 Part
1): 95561.
[81]
Neas LM, Dockery DW, Burge H, Koutrakis P, Speizer FE. Fungus spores,
air pollutants, and
other determinants of peak expiratory flow rates in children. Am J
Epidemiol 1996; 143(8):
797807.
[82]
Delfino RJ, Zeiger RS, Seltzer JM et al. The effect of outdoor fungal
spore concentrations on
daily asthma severity. Environ Health Perspect 1997; 105(6): 62235.
[83]
Dales RE, Cakmak S, Judek S et al. Influence of outdoor aeroallergens on
hospitalization for
asthma in Canada. J Allergy Clin Immunol 2004; 113: 3036.
[84]
Liccorish K, Novey H, Kozak P, Fairshter R, Wilson A. Role of Alternaria
and Penicillium spores
in the pathogenesis of asthma. J Allergy Clin Immunol 1985; 76(6):
81925.
[85]
O'Halloren M, Yungiger J, Offord K et al. Exposure to an aeroallergen as
a possible precipitating
factor in respiratory arrest in young patients with asthma. N Engl J Med
1991; 324(6): 35963.
[86]
Zureik M, Neukirch C, Leynaert B, Laird R, Bousquet J. Sensitization to
airborne moulds and
severity of asthma: cross sectional study from European Community
Respiratory Health Survey.
Br Med J 2002; 325(7361): 4114.
[87]
Gergen PJ, Turkeltaub PC. The association of individual allergen
reactivity with respiratory
disease in a national sample: data from the second National Health and
Nutrition Examination
Survey, 19761980 (NHANES II). J Allergy Clin Immunol 1992; 90(4 Pt 1):
57988.
[88]
Tariq SM, Matthews SM, Stevens M, Hakim EM. Sensitization to Alternaria
and Cladosporium
by the age of 4 years. Clin Exp Allergy 1996; 26(7): 7948.
[89]
Perzanowski MS, Sporik R, Squillance SP et al. Association of
sensitization to Alternaria
allergens with asthma among school aged children. J Allergy Clin Immunol
1998; 101(5): 62632.
[90]
Nelson RP, DiNiccolo R, Fernandez-Caldas E, Seleznick MJ, Lockey R, Good
RA. Allergen
specific IgE levels and mite allergen exposure in children with acute
asthma first seen in an
emergency department and in nonasthmatic control subjects. J Allergy
Clin Immunol 1996; 98(2):
3828.
[91]
Lander F, Meyer HW, Norn S. Serum IgE specific to indoor moulds,
measured by basophil
histamine release, is associated with building-related symptoms in damp
buildings. Inflamm Res
2001; 50: 22731.
[92] Schubert M. Medical treatment of allergic fungal sinusitis. Ann
Allergy Asthma Immunol 2000;
85(2): 90101.
[93] Greenberger P. Allergic bronchopulmonary aspergillosis, allergic
fungal sinusitis and hypersensi-
tivity pneumonitis. Clin Allergy Immunol 2002; 16: 44968.
[94] Ponikau JU, Sherris R, Kern EB. The diagnosis and incidence of
allergic fungal sinusitis. Mayo
Clinic Proc 1999; 74: 87784.
[95] Lebowitz R, Waltzman M, Jacobs J, Pearlman A, Tierno P. Isolation
of fungi by standard
laboratory methods in patients with chronic rhinosinusitis. Laryngoscope
2002; 112(12): 218991.
[96] Rains BM, Mineck CW. Treatment of allergic fungal sinusitis with
high-dose itraconazole. Am
J Rhinol 2003; 17(1): 18.
[97]Apostolakos M, Rossmore H, Beckett W. Hypersensitivity pneumonitis
from ordinary residential
exposures. Environ Health Perspect 2001; 109(9): 97981.
[98] Kita T, Nishi K, Fujimura M et al. A case of hypersensitivity
pneumonitis caused by Humicola
fuscoatra. Respirology 2003; 8: 958.
[99] Ando M, Yoshida K, Soda K, Araki S. Specific bronchoalveolar lavage
IgA antibody in patients
with summer type hypersensitivity pneumonitis induced by Trichosporon
cutaneum. Annu Rev
Resp Dis 1986; 134: 1779.
[100]Centers for Disease Control (CDC): Pulmonary hemorrhage/hemosiderosis
among infants,
Cleveland, Ohio, 19936. MMWR 1997; 46: 335.
[101] Montana E, Etzel R, Allan T, Horgan T, Dearborn D. Environmental
risk factors associated with
pediatric idiopathic pulmonary hemorrhage and hemosiderosis in a
Cleveland community.
Pediatrics 1997; 99: 11724.
[102] Etzel R, Montana E, Sorenson W et al. Acute pulmonary hemorrhage
in infants associated with
exposure to Stachybotrys atra and other fungi. Arch Pediatr Adolesc Med
1998; 152: 75762.
[103] Vesper S, Dearborn D, Yike I, Sorenson W, Haugland R. Hemolysis,
toxicity and randomly
amplified polymorphic DNA analysis of Stachybotrys chartarum strains.
Appl Environ Microbiol
1999; 65(7): 317581.
[104] Dearborn D, Smith P, Dahms B et al. Clinical profile of 30 infants
with acute pulmonary
hemorrhage in Cleveland. Pediatrics 2002; 110(3): 62737.
[105] Center for Disease Control and Prevention (CDC). Update: Pulmonary
hemorrhage/hemosi-
derosis among infants, Cleveland, Ohio 19936. MMWR 2000; 49: 18184
[106] Etzel T. Stachybotrys. Curr Opin Pediatr 2003; 15(1): 1036.
[107] Vesper S, Magnuson M, Dearborn D, Yike I, Haugland R. Initial
characterization of the
hemolysin stachylysin from Stachybotrys chartarum. Infect Immun 2001;
69(2): 9126.
[108] Vesper S, Vesper MJ. Stachylysin may be a cause of hemorrhaging in
humans exposed to
Stachybotrys chartarum. Infect Immun 2002; 70(4): 20659.
[109] Yike I, Allan T, Sorenson W, Dearborn D. Highly sensitive protein
translation assay for
trichothecene toxicity in airborne particulates: comparison with
cytotoxicity assays. Appl Environ
Microbiol 1999; 65(1): 8894.
[110] Johanning E, Biagini R, Hull D, Morey P, Jarvis B, Landsbergis P.
Health and immunology
study following exposure to toxigenic fungi (Stachybotrys chartarum) in
a water-damaged office
environment. Int Arch Environ Health 1996; 68: 20718.
[111] Elidemir O, Colasurdo G, Rossmann S, Fan L. Isolation of
Stachybotrys from the lung of a child
with pulmonary hemosiderosis. Pediatrics 1999; 104(4 Part1): 9646.
[112] Hooper D. Molecular evaluation for autopsy and clinical tissue in
patients. Presented at the 22nd
Annual Symposium on Man and His Environment in Health and Disease,
Dallas, Texas, 27 June
2004.
[113] Vojdani A, Campbell A, Kashanian A, Vojdani E. Antibodies against
molds and mycotoxins
following exposure to toxigenic fungi in water-damaged building. Arch
Environ Health 2003;
58(6): 32436.
[114] Vojdani A, Thrasher J, Madison R, Gray M, Heuser G, Campbell A.
Antibodies to molds and
satratoxin individuals in a water-damaged building. Arch Environ Health
2003; 58(7): 42132.
[115] Savilahti R, Uitti J, Laippala P, Hussman T, Reiman M.
Immunoglobulin G antibodies of
children exposed to microorganisms in a water-damaged school. Pediatr
Allergy Immunol 2002;
13(6): 43842.
[116] Patovirta RL, Reiman M, Husman T, Haverinen U, Toivola M,
Nevalainen A. Mould specific
IgG antibodies connected with sinusitis in teachers of a mould damaged
school: a 2 year follow up
study. Int J Occup Med Environ Health 2003; 16(3): 22130.
[117] Taskinen TM, Laitinen S, Nevalainen A et al. Immunoglobulin G
antibodies to moulds in school-
children from moisture problem schools. Allergy 2002; 57(1): 916.
[118] Malkin R, Martinez K, Marinovich V, Wilcox T, Wall D, Biagini R.
The relationship between
symptoms and IgG and IgE antibodies in an office environment. Environ
Res 1998; 76(2): 8593.
[119] Dales R, Miller D, White J, Dulberg C, Lazarovitis A. Incidence of
residential fungal
contamination on peripheral blood lymphocyte populations in children.
Arch Environ Health
1998; 53(3): 1905.
[120] Vojdani A. Health effects and immunotoxicology of toxigenic molds
and mycotoxins. Presented
at the 21st International Symposium of Man and His Environment in Health
and Disease, Dallas,
Texas, 20 June 2003.
[121] Beijer L, Thorn J, Rylander R. Mould exposure at home relates to
inflammatory markers in
blood. Eur Resp J 2003; 21(2): 31722.
[122] Bondy G, Pestka J. Immunomodulation by fungal toxins. J Toxicol
Environ Health B 2000; 3(2):
10943.
[123] Berek L, Petri IB, Msterhazy A, Teren J, Molnar J. Effects of
mycotoxins on human immune
functions in vitro. Toxicol In Vitro 2001; 15(1): 2530.
[124] Singer R. Neurotoxicity Guidebook. New York: Van Nostrand Reinold,
1990.
[125] Gray M, Kilburn K, Crago R. Molds, mycotoxins and public health:
summary of 195 patients
treated collaboratively. Presented at the American Public Health
Association (APHA) Meeting,
Philadelphia, Pennsylvania, 11 November 2002.
[126] Crago BR, Gray M, Nelson L, Davis M, Arnold L, Thrasher J.
Psychological, neuropsycho-
logical and electrocortical effects of mixed mold exposure. Arch Environ
Health 2003; 58(8):
45263.
[127] Simon T. Neurotoxicitymold exposure versus all causes. Presented
at the 21st Annual
Symposium on Man and His Environment in Health and Disease, Dallas,
Texas, 1922 June
2003.
[128] Gordon W, Johanning E, Haddad L. Cognitive impairment associated
with exposure to toxigenic
fungi. Presented at the 3rd International Conference on Fungi,
Mycotoxins and Bioaerosols,
Saratoga Springs, New York, 2325 September 1998. In: Bioaerosols, Fungi
and Mycotoxins:
Health Effects. Assessments, Prevention and Control. Albany, New York:
Eastern New York
Center for Environmental and Occupational Health, 1999.
[129] Didricksen N. Neurocognitive deficits in individuals exposed to
toxigenic molds. Presented at the
21st Annual Symposium on Man and His Environment in Health and Disease,
Dallas, Texas,
1922 June 2003.
[130] Baldo JV, Ahmad L, Ruff R. Neuropsychological performance of
patients following mold
exposure. Appl Neuropsychol 2002; 9(4): 193202.
[131] Anyanwu E, Campbell A, Vojdani A. Neurophysiological effects of
chronic indoor environmental
toxic mold exposure on children. Sci World J 2003; 3(4): 28190.
[132] Boysen SR, Rozanski EA, Chan DL, Grobe TL, Fallon MJ, Rush J.
Tremorgenic mycotoxicosis
in four dogs from a single household. J Am Vet Med Assoc 2002; 221(10):
14414.
[133] Young DL, Villar D, Carson TL, Ierman PM, Moore RA, Bottoff MR.
Tremorgenic mycotoxin
intoxication with penitrem A and roquefortine in two dogs. J Am Vet Med
Assoc 2002; 222(1):
523.
[134] Naude TW, O'Brien OM, Rundberget T, McGregor AD, Roux C, Flaoyen
A. Tremorogenic
neuromycotoxicosis in 2 dogs ascribed to ingestion of penitrem A and
possibly roquefortine in
rice contaminated with Penicillium crustosum. J S Afr Vet Assoc 2002;
73(4): 2115.
[135] Chen JW, Luo YL, Hwang MJ, Peng FC, Ling KH. Territrem B. a
tremorgenic mycotoxin that
inhibits acetylcholinesterase with a noncovalent yet irreversible
binding mechanism. J Biol Chem
1999; 274(49): 3491623.
[136] Krogh P, Hald B, Pedersen J. Occurrence of ochratoxin A and
citrinin in cereals associated with
mycotoxic porcine nephropathy. Acta Path Micro Scand 1973; 81 Sect B:
68995.
[137] Castegnaro M, Plestina R, Dirheimer O, Chernosemsky IN, Barsch H.
Mycotoxins, endemic
nephropathy and urinary tract tumors. IARC Sci Pub 1991; 115: 1340.
[138] Kristensen P, Irgens L, Andersen A, Bye AS, Sundheim L.
Gestational age, birth weight, and
perinatal death among births to Norwegian farmers, 19671991. Am J
Epidemiol 1997; 146:
32938.
[139] Kristensen P, Andersen A, Irgens L. Hormone-dependent cancer and
adverse reproductive
outcomes in farmers familieseffects of climatic conditions favoring
fungal growth in grain.
Scand J Work Health 2000; 26(4): 3317.
[140] Diekman M, Green M. Mycotoxins and reproduction in domestic
livestock. J Anim Sci 1992; 70:
161527.
[141] Cotran RS. Robbins Pathologic Basis of Disease, 5th edn. New York:
WB Saunders, 1994, p. 914.
[142] Cheta D. Animal models of type 1 (insulin-dependent) diabetes
mellitus. J Pediatr Endocrinol
Metab 1998; 11(1): 119.
[143] Hoffmeister PA, Storer BE, Sanders JE. Diabetes mellitus in
long-term survivors of pediatric
hematopoietic cell transplantation. J Pediatr Hematol Oncol 2004; 26(2):
8190.
[144] Eggleston PA. Environmental control for fungal allergen exposure.
Curr Allergy Asthma Rep
2003; 3(5): 4249.
[145] Heuser G, Axelrod P, Heuser S. Defining chemical injury: a
diagnostic protocol and profile of
chemically injured civilians, industrial workers and Gulf War veterans.
Int Perspect Public Health
2000; 13: 116.
[146] Marshall L, Weir E, Abelsohn A, Sanborn MD. Identifying and
managing adverse environmental
effects: 1) taking an exposure history. Can Med Assoc J 2002; 166(8):
104955.
[147] Dales RE, Miller D, McMullen E. Indoor air quality and health:
validity and determinants of
reported home dampness and molds. Int J Epidemiol 1997; 26: 1204.
[148] Macher J (ed.) Bioaerosols: Assessment and Control. American
Conference of Governmental and
Industrial Hygienists (ACGIH), Cincinnati, Ohio, 1999.
[149] Portnoy JM, Barnes CS, Kennedy K. Sampling for indoor fungi. J
Allergy Clin Immunol 2004;
113: 18998.
[150] Institute of Medicine Committee on the Health Effects of Indoor
Allergens: Engineering Control
Strategies. Allergens: Assessing and Controlling Adverse Health Effects.
Engineering Control
Strategies. Washington, DC: National Academy Press, 1993, 20632.
[151] Institute for Inspection, Cleaning and Restoration. IICRC S520
Standard and reference guide for
professional mold remediation. Vancouver, Washington: IICRC Press, 2003.
[152] Higgins BG, Francis HC, Yates G et al. Environmental exposure to
air pollution and allergens
and peak flow changes. Eur Resp J 2000; 16(1): 616.
[153] Thorn J, Brisman J, Toren K. Adult-onset asthma is associated with
self-reported mold or
environmental tobacco smoke in the home. Allergy 2001; 56: 28792.
[154] Chen WY, Tseng HI, Wu MT et al. Synergistic effect of multiple
indoor allergen sources on
atopic symptoms in primary school children. Environ Res 2003; 93(1):
18.
[155] Skoner DP. Viral infection and allergy: lower airway. Allergy
Asthma Proc 2002; 23(4): 22932.
[156] Fireman P. Virus-provoked rhinitis in patients who have allergies.
Allergy Asthma Proc 2002;
23(2): 99102.
[157] Hirsch D, Hirsch R, Kalbfleish S. Effect of central
air-conditioning and meterological factors on
indoor spore counts. J Allergy Clin Immunol 1978; 62(1): 226.
[158] Sheretz RJ, Belani A, Kramer BS et al. Impact of air filtration on
nosocomial Aspergillus
infections. Am J Med 1987; 83(4): 70918.
[159] Panackal A, Dahlman A, Keil K et al. Outbreak of invasive
aspergillosis among renal transplant
patients. Transplantation 2003; 75(7): 10503.
[160] Oren I, Haddad N, Finkelstein R, Rowe J. Invasive pulmonary
aspergillosis in neutropenic
patients during hospital construction: before and after chemoprophylaxis
and institution of
HEPA filters. Am J Hematol 2001; 66(4): 25762.
[161] Loo V, Betrand C, Dixon C et al. Control of
construction-associated nosocomial aspergillosis in
an antiquated hematology unit. Infect Control Hosp Epidemiol 1996;
17(6): 3604.
[162] Iwen P, Davis J, Reed EC, Winfield BA, Hinrichs SH. Airborne
fungal spore monitoring in a
protective environment during hospital construction, and correlation
with outbreak of invasive
aspergillosis. Infect Control Hosp Epidemiol 1994; 15(5): 3036.
[163] Hahn T, Cummings K, Michalek AM, Lipman B, Segel B, McCarthy P.
Efficacy of high-
efficiency particulate air filtration in preventing aspergillosis in
immunocompromised patients
with hematologic malignancies. Infect Control Hosp Epidemiol 2002;
23(9): 52531.
[164] Cornet M, Levy V, Fleury L et al. Efficacy of prevention by
high-efficiency particulate air
filtration or laminar airflow against Aspergillus airborne contamination
during hospital
renovation. Infect Control Hosp Epidemiol 1999; 20(7): 50813.
[165] Withington S, Chambers ST, Beard ME et al. Invasive aspergillosis
in severely neutropenic
patients over 18 years: impact of intranasal amphotericin B and HEPA
filtration. J Hosp Infect
1998; 38(1): 118.
[166] Annaisie EJ, Stratton SL, Dignani MC et al. Pathogenic Aspergillus
species recovered from a
hospital water system: a 3 year prospective study. Clin Infect Dis 2002;
34(6): 7809.
[167] Annaisie EJ, Stratton SL, Dignani MC et al. Cleaning patient
shower facilities: a novel approach
to reducing patient exposure to aerosolized Aspergillus species and
other opportunistic molds.
Clin Infect Dis 2002; 35(8): E868.
[168] Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M.
Injective versus sublingual
immunotherapy in Alternaria tenuis allergic patients. J Invest Allergol
Clin Immunol 1996; 6(1):
5562.
[169] Helbling A, Reimers A. Immunotherapy in fungal allergy. Curr
Allergy Asthma Rep 2003; 3(5):
44753.
[170] Galvano F, Piva A, Ritieni A, Galvano G. Dietary strategies to
counteract the effects of
mycotoxins: a review. J Food Protect 2001; 64(1): 12031.
[171] Atroshi F, Rizzo A
©Mold Help 2001-2005 All rights
reserved
Return to MH
|